381 related articles for article (PubMed ID: 12902441)
1. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
J Natl Cancer Inst; 2003 Aug; 95(15):1118-27. PubMed ID: 12902441
[TBL] [Abstract][Full Text] [Related]
2. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
[TBL] [Abstract][Full Text] [Related]
6. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
Pujol JL; Daurès JP; Rivière A; Quoix E; Westeel V; Quantin X; Breton JL; Lemarié E; Poudenx M; Milleron B; Moro D; Debieuvre D; Le Chevalier T
J Natl Cancer Inst; 2001 Feb; 93(4):300-8. PubMed ID: 11181777
[TBL] [Abstract][Full Text] [Related]
7. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1996 Dec; 23(6 Suppl 16):7-10. PubMed ID: 9007113
[TBL] [Abstract][Full Text] [Related]
9. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
[TBL] [Abstract][Full Text] [Related]
10. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Salgia R; Stille JR; Weaver RW; McCleod M; Hamid O; Polzer J; Roberson S; Flynt A; Spigel DR
Lung Cancer; 2017 Mar; 105():7-13. PubMed ID: 28236984
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule.
Groen HJ; Fokkema E; Biesma B; Kwa B; van Putten JW; Postmus PE; Smit EF
J Clin Oncol; 1999 Mar; 17(3):927-32. PubMed ID: 10071286
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer.
Birch R; Weaver CH; Hainsworth JD; Bobo C; Greco FA
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-135-S12-137. PubMed ID: 9331138
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
Lee YC; McCrystal MR; Christmas TI
N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
Hesketh PJ; McCoy J; Dunphy FR; Bearden JD; Weiss GR; Giguere JK; Atkins JN; Dakhil SR; Kelly K; Crowley JJ; Gandara DR
J Thorac Oncol; 2006 Nov; 1(9):991-5. PubMed ID: 17409984
[TBL] [Abstract][Full Text] [Related]
17. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
18. Phase II and III studies with carboplatin in small cell lung cancer.
Gatzemeier U; Hossfeld DK; Neuhauss R; Reck M; Achterrath W; Lenaz L
Semin Oncol; 1992 Feb; 19(1 Suppl 2):28-36. PubMed ID: 1329220
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
[TBL] [Abstract][Full Text] [Related]
20. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]